Regeneron Pharmaceuticals Files Q1 2026 10-Q Report
Ticker: REGN · Form: 10-Q · Filed: Apr 29, 2026 · CIK: 0000872589
| Field | Detail |
|---|---|
| Company | Regeneron Pharmaceuticals, Inc. (REGN) |
| Form Type | 10-Q |
| Filed Date | Apr 29, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, financials
Related Tickers: REGN
TL;DR
REGN Q1 2026 10-Q filed. Financials and exec certs are in.
AI Summary
Regeneron Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ending March 31, 2026. The filing includes financial statements, certifications from its CEO and CFO, and detailed XBRL data. The company's mailing and business address is 777 Old Saw Mill River Road, Tarrytown, NY 10591.
Why It Matters
This filing provides investors with the latest financial performance and operational details for Regeneron Pharmaceuticals, Inc. as of March 31, 2026.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing and does not inherently present new risks.
Key Numbers
- 1659637 — 10-Q iXBRL Document Size (Size of the main quarterly report document.)
- 6434158 — Complete Submission Text File Size (Total size of the complete submission text file.)
Key Players & Entities
- REGENERON PHARMACEUTICALS, INC. (company) — Filer
- 0000872589 (company) — CIK
- 2026-04-29 (date) — Filing Date
- 2026-03-31 (date) — Period of Report
- 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 (address) — Mailing and Business Address
FAQ
What is the filing date of this 10-Q report?
The filing date of this 10-Q report is April 29, 2026.
What period does this 10-Q report cover?
This 10-Q report covers the period ending March 31, 2026.
What is Regeneron Pharmaceuticals, Inc.'s CIK number?
Regeneron Pharmaceuticals, Inc.'s CIK number is 0000872589.
Where is Regeneron Pharmaceuticals, Inc. located?
Regeneron Pharmaceuticals, Inc.'s mailing and business address is 777 Old Saw Mill River Road, Tarrytown, NY 10591.
What types of certifications are included in this filing?
This filing includes certifications from the CEO and CFO pursuant to Rule 13a-14(a), and certifications from both the CEO and CFO pursuant to 18 U.S.C Section 1350.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 29, 2026 regarding REGENERON PHARMACEUTICALS, INC. (REGN).